RETINALGENIX TECHNOLOGIES INC Financials
This page shows RETINALGENIX TECHNOLOGIES INC (RTGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
RETINALGENIX TECHNOLOGIES INC passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, RETINALGENIX TECHNOLOGIES INC generates $0.17 in operating cash flow (-$742K OCF vs -$4.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
RETINALGENIX TECHNOLOGIES INC reported -$4.3M in net income in fiscal year 2024. This represents a decrease of 106.7% from the prior year.
RETINALGENIX TECHNOLOGIES INC earned $-0.24 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 100.0% from the prior year.
RETINALGENIX TECHNOLOGIES INC held $6K in cash against $0 in long-term debt as of fiscal year 2024.
RETINALGENIX TECHNOLOGIES INC had 19M shares outstanding in fiscal year 2024. This represents an increase of 5.0% from the prior year.
RETINALGENIX TECHNOLOGIES INC invested $373K in research and development in fiscal year 2024. This represents a decrease of 28.8% from the prior year.
RTGN Income Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $20K+41.7% | $14K+9.2% | $13K | N/A | $103K+24.2% | $83K-0.2% | $83K | N/A |
| SG&A Expenses | $270K-29.6% | $384K+12.5% | $341K | N/A | $244K-33.8% | $369K+12.1% | $329K | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $9600.0% | $9600.0% | $960 | N/A | $9600.0% | $9600.0% | $960 | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$569K+12.4% | -$649K-10.6% | -$587K | N/A | -$644K+2.9% | -$664K+69.1% | -$2.1M | N/A |
| EPS (Diluted) | $-0.03+11.8% | $-0.03-13.3% | $-0.03 | N/A | $-0.040.0% | $-0.04+66.7% | $-0.12 | N/A |
RTGN Balance Sheet
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7K-16.5% | $8K-29.7% | $12K-20.2% | $15K-83.2% | $89K+2.1% | $87K+72.3% | $51K+32282.7% | $156 |
| Current Assets | $92-89.0% | $839-77.4% | $4K-38.8% | $6K-92.3% | $79K-9.0% | $87K+72.5% | $50K | $0 |
| Cash & Equivalents | $92-89.0% | $839-77.4% | $4K-38.8% | $6K-92.3% | $79K-9.0% | $87K+72.5% | $50K | $0 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.2M+9.6% | $2.0M+18.4% | $1.7M+13.7% | $1.5M-24.0% | $1.9M+2.4% | $1.9M+21.0% | $1.6M+11.6% | $1.4M |
| Current Liabilities | $2.2M+9.6% | $2.0M+18.5% | $1.7M+13.8% | $1.5M-24.0% | $1.9M | N/A | N/A | $1.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.2M-9.7% | -$2.0M-18.8% | -$1.7M-14.0% | -$1.5M+21.1% | -$1.9M-2.4% | -$1.8M-19.3% | -$1.5M-8.0% | -$1.4M |
| Retained Earnings | -$17.2M-3.4% | -$16.7M-4.1% | -$16.0M-3.8% | -$15.4M-6.0% | -$14.6M-4.6% | -$13.9M-5.0% | -$13.3M-19.3% | -$11.1M |
RTGN Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$104K+25.3% | -$139K+25.7% | -$187K-0.4% | -$186K+24.5% | -$247K-70.5% | -$145K+11.6% | -$164K+43.5% | -$290K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $103K-24.3% | $136K-26.3% | $185K+63.1% | $113K-52.6% | $239K+31.9% | $181K-15.4% | $214K-26.1% | $290K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RTGN Financial Ratios
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8124.4%-382.2pp | -7742.2%-2820.1pp | -4922.1% | N/A | -725.1%+37.5pp | -762.6%+3485.2pp | -4247.8% | N/A |
| Current Ratio | 0.000.0 | 0.000.0 | 0.000.0 | 0.00-0.0 | 0.04 | N/A | N/A | 0.00 |
| Debt-to-Equity | -1.000.0 | -1.000.0 | -1.010.0 | -1.01+0.0 | -1.050.0 | -1.05-0.0 | -1.03-0.0 | -1.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is RETINALGENIX TECHNOLOGIES INC profitable?
No, RETINALGENIX TECHNOLOGIES INC (RTGN) reported a net income of -$4.3M in fiscal year 2024.
What is RETINALGENIX TECHNOLOGIES INC's earnings per share (EPS)?
RETINALGENIX TECHNOLOGIES INC (RTGN) reported diluted earnings per share of $-0.24 for fiscal year 2024. This represents a -100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is RETINALGENIX TECHNOLOGIES INC's operating cash flow?
RETINALGENIX TECHNOLOGIES INC (RTGN) generated -$742K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are RETINALGENIX TECHNOLOGIES INC's total assets?
RETINALGENIX TECHNOLOGIES INC (RTGN) had $15K in total assets as of fiscal year 2024, including both current and long-term assets.
How much does RETINALGENIX TECHNOLOGIES INC spend on research and development?
RETINALGENIX TECHNOLOGIES INC (RTGN) invested $373K in research and development during fiscal year 2024.
How many shares does RETINALGENIX TECHNOLOGIES INC have outstanding?
RETINALGENIX TECHNOLOGIES INC (RTGN) had 19M shares outstanding as of fiscal year 2024.
What is RETINALGENIX TECHNOLOGIES INC's current ratio?
RETINALGENIX TECHNOLOGIES INC (RTGN) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is RETINALGENIX TECHNOLOGIES INC's debt-to-equity ratio?
RETINALGENIX TECHNOLOGIES INC (RTGN) had a debt-to-equity ratio of -1.01 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is RETINALGENIX TECHNOLOGIES INC's return on assets (ROA)?
RETINALGENIX TECHNOLOGIES INC (RTGN) had a return on assets of -28909.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is RETINALGENIX TECHNOLOGIES INC's cash runway?
Based on fiscal year 2024 data, RETINALGENIX TECHNOLOGIES INC (RTGN) had $6K in cash against an annual operating cash burn of $742K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is RETINALGENIX TECHNOLOGIES INC's debt-to-equity ratio negative or unusual?
RETINALGENIX TECHNOLOGIES INC (RTGN) has negative shareholder equity of -$1.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is RETINALGENIX TECHNOLOGIES INC's Piotroski F-Score?
RETINALGENIX TECHNOLOGIES INC (RTGN) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are RETINALGENIX TECHNOLOGIES INC's earnings high quality?
RETINALGENIX TECHNOLOGIES INC (RTGN) has an earnings quality ratio of 0.17x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.